OncoMatch/Clinical Trials/NCT07015242
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Is NCT07015242 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for lymphoma.
Treatment: Rituximab · Methotrexate · Procarbazine · Temozolomide · Liso-cel · Fludarabine · Cyclophosphamide · Calcium folinate — The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: high dose methotrexate-based regimen (methotrexate)
Participant must be suitable, per investigator, to receive a high dose methotrexate (HD-MTX) based treatment regimen
Must have received: standard of care regimens
Prior to signing ICF, anti-cancer therapy for the treatment of PCNSL must only include standard of care regimens, with or without corticosteroids given for disease-related symptoms
Cannot have received: CAR-T cell therapy
Prior treatment with CAR T-cell or any other gene therapy product that utilizes human genome-editing technology
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 307 · Stanford, California
- Local Institution - 0305 · Aurora, Colorado
- Local Institution - 305 · Aurora, Colorado
- Local Institution - 308 · Tampa, Florida
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify